161 related articles for article (PubMed ID: 31888982)
1. QnAs with H. Michael Shepard and Dennis J. Slamon.
Davis TH
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):796-798. PubMed ID: 31888982
[No Abstract] [Full Text] [Related]
2. H. Michael Shepard, Dennis J. Slamon, and Axel Ullrich honored with the 2019 Lasker~DeBakey Clinical Medical Research Award.
Williams CL
J Clin Invest; 2019 Oct; 129(10):3963-3965. PubMed ID: 31499488
[No Abstract] [Full Text] [Related]
3. Herceptin: A First Assault on Oncogenes that Launched a Revolution.
Sawyers CL
Cell; 2019 Sep; 179(1):8-12. PubMed ID: 31519311
[TBL] [Abstract][Full Text] [Related]
4. HER-2/neu testing comes of age.
Wisecarver JL
Am J Clin Pathol; 1999 Mar; 111(3):299-301. PubMed ID: 10078102
[No Abstract] [Full Text] [Related]
5. Recent Developments and Future Directions with HER-2 in Breast Cancer and Other Tumor Types. Proceedings of a roundtable. August 11-14, 1999. Olympic Valley, California, USA.
Semin Oncol; 2000 Dec; 27(6 Suppl 11):1-100, quiz 101-10. PubMed ID: 11245159
[No Abstract] [Full Text] [Related]
6. [Herceptin].
Morginstin T; Shani S; Shemer J
Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
[No Abstract] [Full Text] [Related]
7. Should we treat HER, too?
Hayes DF
J Clin Oncol; 1996 Mar; 14(3):697-9. PubMed ID: 8622013
[No Abstract] [Full Text] [Related]
8. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
[No Abstract] [Full Text] [Related]
9. Targeting HER2 in prostate cancer: where to next?
Solit DB; Rosen N
J Clin Oncol; 2007 Jan; 25(3):241-3. PubMed ID: 17235040
[No Abstract] [Full Text] [Related]
10. What is the ideal HER2 test for Herceptin therapy?
Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
[No Abstract] [Full Text] [Related]
11. Focus on ERBB2.
Benusiglio PR
Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
[No Abstract] [Full Text] [Related]
12. Predicting response to herceptin therapy.
Lipton A; Leitzel K; Ali S
Clin Cancer Res; 2004 Mar; 10(5):1559-60. PubMed ID: 15014003
[No Abstract] [Full Text] [Related]
13. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
14. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
15. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
16. Optimising the Role of Herceptin in Breast Cancer. Symposium proceedings. Monte Carlo, June 19-21, 2000.
Oncology; 2001; 61 Suppl 2():1-91. PubMed ID: 11758500
[No Abstract] [Full Text] [Related]
17. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
18. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
19. HER2/neu in the management of invasive breast cancer.
Meric F; Hung MC; Hortobagyi GN; Hunt KK
J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
[No Abstract] [Full Text] [Related]
20. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
Arteaga CL
Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
